Vaccine Makers Already Testing Their Shots Against Omicron Variant


Adobe Stoick

MONDAY, Nov. 29, 2021 (HealthDay News) -- As concerns about the new Omicron variant grow, vaccine makers say they're already working on ways to protect people against the potential new threat.

Pfizer said it and its partner BioNTech could develop and produce a "tailor-made vaccine" in about 100 days if a "vaccine-escape" variant emerges, NBC News reported.

Meanwhile, Moderna said it was employing a three-pronged strategy against the Omicron variant.

“From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves. The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant,” Moderna CEO Stéphane Bancel, said in a statement.

“We have three lines of defense that we are advancing in parallel: we have already evaluated a higher dose booster of mRNA-1273 [100 µg], second, we are already studying two multi-valent booster candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant and data is expected in the coming weeks, and third, we are rapidly advancing a Omicron-specific booster candidate [mRNA-1273.529],” Bancel added.

So far, existing vaccines have proven effective against prior coronavirus variants, including the Delta variant, but it's wise to be preparing for updated vaccines, said Deepti Gurdasani, clinical epidemiologist at Queen Mary University of London.

It's also important to try to contain the new variant's spread.

“It’s possible that Pfizer might come up with this vaccine in three or four months’ time and by the time it becomes available, there’s a new globally dominant variant,” Gurdasani told NBC News. “So, vaccine development and re-engineering has to go hand in hand with efforts to contain transmission, which is the only way that we’re going to be able to get on top of the virus adaptation.”

The limited amount of data from South Africa and elsewhere has raised legitimate concerns about the Omicron variant, according to Pennsylvania State University's David Kennedy, who studies the evolution of infectious diseases.

“It’s enough to make me think we should watch this and be concerned but not enough to make me panic -- yet,” he told NBC News.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on safe travel during the pandemic.

SOURCE: Moderna, news release, Nov. 26, 2021; NBC News

Related Stories

No stories found.